December 27, 2005 – NeoPharm won the Most Improved award in biotech today, after announcing that the data monitoring committee recommended continuing the Phase III trial of its brain cancer treatment; Bristol-Myers Squibb won FDA approval for its rheumatoid arthritis drug, Orencia; InterMune out-licensed its Gram positive antibiotic, oritavancin, to Targanta Therapeutics; Pfizer paid $50 million for a 12% stake in Perlegen Sciences; Shire received an approvable letter for its Daytrana patch as an ADHD therapy; and Applied Biosystems will pay $273 million to buy a unit of Ambion. The Centient Biotech 200™ was down 35 points at 3974.36, a loss of .88%. More details...
